P. He

发表

Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.

M. Kudo, P. Galle, J. Furuse, 2022, NEJM evidence.

Efficacy, tolerability, and biologic activity of a novel regimen of tremelimumab (T) in combination with durvalumab (D) for patients (pts) with advanced hepatocellular carcinoma (aHCC).

A. Gasbarrini, M. Kudo, J. Bruix, 2020 .

Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.

M. Kudo, J. Furuse, G. Abou-Alfa, 2022, Journal of Clinical Oncology.

Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.

J. W. Kim, M. Ikeda, Li‐Tzong Chen, 2022, NEJM evidence.

Durvalumab with or without tremelimumab versus the EXTREME regimen as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck: KESTREL, a randomized, open-label, phase III study.

J. Machiels, T. Seiwert, A. Psyrri, 2022, Annals of oncology : official journal of the European Society for Medical Oncology.

Plasma-based tumor mutational burden (bTMB) as predictor for survival in phase III EAGLE study: Durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) after platinum failure.

R. Ferris, L. Licitra, R. Haddad, 2020 .

A weighted log‐rank test and associated effect estimator for cancer trials with delayed treatment effect

Chang Yu, H. Nian, Xiang Huang, 2021, Pharmaceutical statistics.

Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial.

T. Powles, M. Galsky, S. Park, 2020, The Lancet. Oncology.

Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study

A. Gasbarrini, M. Kudo, J. Bruix, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

697O A phase III, randomized, open-label study of first-line durvalumab (D) with or without tremelimumab (T) vs standard of care chemotherapy in patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE)

T. Powles, M. Galsky, A. Gupta, 2020 .

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

G. Abou-Alfa, Diansong Zhou, R. Kelley, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN.

L. Wyrwicz, Ken Kato, Ming Chen, 2022, Journal of Clinical Oncology.

O-6 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma

A. Gasbarrini, M. Kudo, J. Bruix, 2020 .

LBA42 COAST: An open-label, randomised, phase II platform study of durvalumab alone or in combination with novel agents in patients with locally advanced, unresectable, stage III NSCLC

R. Herbst, D. Camidge, F. Barlesi, 2021, Annals of Oncology.

708P PD-L1 as a predictor of survival in patients with metastatic urothelial carcinoma (mUC) from the phase III DANUBE trial of durvalumab (D) or durvalumab plus tremelimumab (D+T) versus standard of care chemotherapy (SoC)

T. Powles, M. Galsky, A. Gupta, 2021, Annals of Oncology.

Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

L. Siu, L. Licitra, R. Haddad, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.